ROLE OF MONTELUKAST ON PERENNIAL ALLERGIC RHINITIS & ASSOCIATED SLEEP DISTURBANC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的假设是，白三烯受体拮抗剂(LRA)孟鲁司特可以减少鼻塞，从而提高鼻腔通畅度，减少夜间睡眠碎片。睡眠碎片的减少将减少白天的嗜睡和疲倦。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypothesis for this study is that a leukotriene receptor antagonist (LRA), Montelukast, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation. This decrease in sleep fragmentation will reduce daytime somnolence and fatigue.